South Texas Accelerated Research Therapeutics, an academic-led research institute in San Antonio, TX, USA, that focuses on the clinical development of new anticancer drugs, recently announced the enrolment of the first patient in a phase 1 trial combining two small molecule kinase inhibitors-MK-2206 and AZD6244, manufactured by rival pharmaceutical companies-which had been shown in preclinical experiments to have synergistic activity. This initiative is thought to be the first time that rival companies have brought together drugs at such an early stage of development.
展开▼
机译：位于美国德克萨斯州圣安东尼奥市的以学术为主导的研究机构南德克萨斯州加速研究治疗学有限公司（South Texas Accelerated Research Therapeutics）最近专注于新型抗癌药物的临床开发，该公司最近宣布第一名患者参加了一项结合两种小分子激酶抑制剂的1期试验-MK-2206和AZD6244，由竞争对手的制药公司生产，在临床前实验中已证明具有协同活性。这项计划被认为是竞争对手公司在如此早期的发展阶段首次将药物整合在一起的举措。
展开▼
